Skip to content

IRBM’s discovery philosophy drives our multi-skilled Experimental Pharmacology team to integrate basic and applied pharmaceutical sciences and successfully deliver your drug discovery program. We provide comprehensive and bespoke support for standalone and integrated discovery projects including preclinical candidate nomination and clinical biomarker endpoint readouts.

  • Our comprehensive suite of automated DMPK, PK and toxicology assays provide rapid and efficient analysis to guide design and testing cycles for all drug discovery programs
  • We use state-of-the-art technology to conduct in silico, in vitro and in vivo studies to select compounds with optimal Absorption, Distribution, Metabolism, Excretion (ADME) properties
  • We conduct in depth druggability studies with small molecules and other modalities such as proteolysis targeting chimeras (PROTACs), molecular glues, oligonucleotides, peptides, and proteins
  • Our agile and skilled scientists are ready to adapt quickly to changes in priorities or project direction
  • We ensure clear accountability through dedicated customer interfaces
FIND OUT MORE ABOUT OUR DEDICATED RESEARCH TEAMS:
  • ADME, pharmacology, toxicology and drug-drug interactions (DDI)
  • Pharmacokinetics (PK), Pharmacodynamics (PD) and bioanalytics
  • Biodistribution, biotransformation and analytical science

Figure 1 ADME in vivo and in vitro Assays (for simplicity, only major SAR driving assays are shown)

ADME/
PHARMACOLOGY

PK, PD
BIOANALYTICS

BIOTRANSFORMATION,
BIODISTRIBUTION,
ANALYTICAL
SCIENCE

Back To Top